Skip to main content
Premium Trial:

Request an Annual Quote

1999 Ends on Positive Note for Biotechnology

Premium

S

AN FRANCISCO--1999 ended on a high note for the biotech industry as interest in sector stocks was renewed and a number of companies completed successful IPOs during the fourth quarter, according to private merchant bank Burrill. Unlike previous quarters when large and mid-sized biotech companies performed better than small ones, even smaller firms fared better as a whole, increasing 72 percent. Burrill credited renewed investor interest in genomics companies such as Abgenix, Celera Genomics, Human Genome Sciences, Incyte Pharmaceuticals, and Millennium Pharmaceuticals, whose stock prices more than doubled during the quarter.

Filed under

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.